Close Menu

NEW YORK (GenomeWeb) – A team led by investigators at Brigham and Women's Hospital, Harvard Medical School, and the Broad Institute has uncovered evidence that checkpoint blockade immunotherapy response may involve shifts in the activity of tumor microenvironment T cells that do not express receptors for the immune checkpoint proteins that such therapies target.

"Our study broadens the focus of what checkpoint blockade therapy may be doing and how it mediates its effects," co-corresponding and co-senior author Ana Anderson, a BWH researcher, said in a statement.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.